Key points from article :
British startup Kneu Health has secured $5.6 million in seed funding to expand its smartphone-based platform that monitors neurodegeneration in real time. Built on Oxford University research, the system enables continuous tracking of conditions like Parkinson’s and dementia.
Using AI-trained models, Kneu’s app analyzes speech, movement, and memory to create predictive biomarkers. These biomarkers help clinicians detect neurological decline earlier and tailor treatment precisely. The company’s dataset, one of the largest globally, includes over 500,000 measures from 1,400 participants.
Kneu’s FDA-cleared technology gives doctors visibility between visits, shifting care from reactive to proactive. Clinical trials within the NHS showed a 30% efficiency gain, reduced emergency visits, and improved patient confidence and independence.
Kneu Health emphasized how “continuous insight” redefines care, allowing earlier interventions and better long-term outcomes.
The round, co-led by Oxford Science Enterprises and Cedars-Sinai, lifts Kneu’s total funding to $11.2 million. The company plans to scale its presence in the US and enhance its dementia-monitoring capabilities.
By turning everyday smartphone interactions into medical insight, Kneu Health is reshaping how clinicians understand and manage neurodegenerative diseases worldwide.
